Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,020
  • Shares Outstanding, K 5,874
  • Annual Sales, $ 3,000 K
  • Annual Income, $ -84,940 K
  • 60-Month Beta 1.06
  • Price/Sales 9.12
  • Price/Cash Flow N/A
  • Price/Book 0.87
Trade ABEO with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 120.23%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,334.47% on 02/10/22
  • IV Low 0.00% on 08/12/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 227
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 7,147
  • Open Int (30-Day) 5,356

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.00
  • Number of Estimates 1
  • High Estimate -1.00
  • Low Estimate -1.00
  • Prior Year -4.00
  • Growth Rate Est. (year over year) +75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.81 +16.27%
on 08/01/22
5.53 -19.89%
on 07/13/22
-1.03 (-18.86%)
since 07/12/22
3-Month
3.68 +20.30%
on 05/25/22
6.13 -27.73%
on 07/11/22
+0.50 (+12.79%)
since 05/12/22
52-Week
3.26 +35.99%
on 05/11/22
34.00 -86.97%
on 09/07/21
-26.82 (-85.82%)
since 08/12/21

Most Recent Stories

More News
Abeona Therapeutics Reports Second Quarter 2022 Financial Results

Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline data expected in late-3Q/early-4Q...

ABEO : 4.43 (-4.94%)
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

RARE : 51.57 (+0.62%)
ABEO : 4.43 (-4.94%)
SRRK : 11.30 (+10.57%)
BNTX : 160.35 (+1.11%)
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq...

ABEO : 4.43 (-4.94%)
Philips (PHG) Expands AI Portfolio With SmartSpeed Solution

Koninklijke Philips (PHG) announces that its latest AI-powered MR acceleration software SmartSpeed will be showcased as part of the AI-powered precision diagnosis portfolio at ECR.

GE : 79.93 (+1.31%)
PHG : 20.21 (+0.25%)
ABEO : 4.43 (-4.94%)
ACRS : 16.80 (unch)
Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant

Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.

PFE : 50.11 (+3.77%)
ABEO : 4.43 (-4.94%)
SESN : 0.7001 (-0.55%)
ROIV : 4.37 (-2.02%)
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

ALKS : 26.15 (+2.67%)
ABEO : 4.43 (-4.94%)
SESN : 0.7001 (-0.55%)
FSTX : 6.50 (-1.07%)
Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug

Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.

ALKS : 26.15 (+2.67%)
ABEO : 4.43 (-4.94%)
ACER : 1.4700 (-0.67%)
SESN : 0.7001 (-0.55%)
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

ALKS : 26.15 (+2.67%)
ABEO : 4.43 (-4.94%)
OBSV : 0.3044 (-1.49%)
SESN : 0.7001 (-0.55%)
Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study

Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.

ALKS : 26.15 (+2.67%)
CLVS : 1.4800 (+2.07%)
ABEO : 4.43 (-4.94%)
SESN : 0.7001 (-0.55%)
FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy

An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.

ALKS : 26.15 (+2.67%)
BLUE : 6.72 (+6.50%)
ABEO : 4.43 (-4.94%)
SESN : 0.7001 (-0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

3rd Resistance Point 5.43
2nd Resistance Point 5.21
1st Resistance Point 4.82
Last Price 4.43
1st Support Level 4.21
2nd Support Level 3.99
3rd Support Level 3.60

See More

52-Week High 34.00
Fibonacci 61.8% 22.26
Fibonacci 50% 18.63
Fibonacci 38.2% 15.00
Last Price 4.43
52-Week Low 3.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar